FrancophonIA/ELRC3.0 huggingface dataset:
English: → Talk to your doctor for further advice on taking acid-lowering medicines with Dovato.
Slovenian: → Posvetujte se z zdravnikom o jemanju zdravil za zmanjševanje kisline skupaj z zdravilom Dovato.
English: Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance.
Slovenian: Študije z lamivudinom kažejo, da so pri bolnikih z okvarjenim delovanjem ledvic plazemske koncentracije (AUC) zaradi manjšega očistka povečane.
English: When possible, avoid chronic coadministration of Dovato with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (eg: xylitol, mannitol, lactitol, maltitol).
Slovenian: Če je mogoče, se izognite kronični sočasni uporabi zdravila Dovato z zdravili, ki vsebujejo sorbitol ali druge osmotsko delujoče polialkohole oziroma monosaharidne alkohole (npr. ksilitol, manitol, laktitol, maltitol).
English: Some people taking combination therapy for HIV develop a condition called osteonecrosis.
Slovenian: Pri nekaterih osebah, ki jemljejo kombinacijo zdravil za HIV, se lahko pojavi bolezen, imenovana osteonekroza.
English: The mean IC50 for 3 HIV-2 isolates was 0.18 nM (range 0.09-0.61).
Slovenian: Povprečna vrednost IC50 proti trem izolatom HIV-2 je bila 0,18 nM (razpon 0,09 - 0,61).
English: Symptoms of infection and inflammation
Slovenian: Simptomi okužbe in vnetja
English: Baseline CD4+ (cells/ mm3)
Slovenian: Izhodiščna vrednost CD4+ (celic/mm
English: AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.
Slovenian: AUC v semenu je bila 7 % in v tkivu danke 17 % ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
English: 4.3 Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: Dovato contains dolutegravir and lamivudine, therefore any interactions identified for these individually are relevant to Dovato.
Slovenian: Zdravilo Dovato vsebuje dolutegravir in lamivudin, zato je katera koli interakcija, povezana s posamezno zdravilno učinkovino, relevantna tudi za zdravilo Dovato.
English: If Dovato is used in patients co-infected with hepatitis B an additional antiviral is therefore generally needed.
Slovenian: Če se zdravilo Dovato uporablja pri bolnikih, ki so sočasno okuženi tudi s hepatitisom B, je običajno treba uporabiti še dodatno protivirusno zdravilo.
English: • difficulty breathing.
Slovenian: • oteženo dihanje
English: • symptoms of infections and inflammation
Slovenian: • simptomi okužb in vnetij
English: In the Phase III studies for the dolutegravir single agent, patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
Slovenian: V študijah faze III za dolutegravir kot posamezno učinkovino so bolniki s sočasno okužbo z virusom hepatitisa B in/ali C smeli biti vključeni v raziskavo pod pogojem, da njihove izhodiščne vrednosti jetrnih testov niso presegle petkratne zgornje meje normale (ULN - upper limit of normal).
English: Always take this medicine exactly as your doctor has told you.
Slovenian: Jemljite zdravilo Dovato tako dolgo, kot vam priporoča zdravnik.
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding in vitro (< 16%- 36% to serum albumin).
Slovenian: V razponu terapevtskih odmerkov lamivudin kaže linearno farmakokinetiko in omejeno vezavo na plazemske proteine in vitro (< 16 % - 36 % vezava na serumski albumin).
English: There are limited pharmacokinetic data on subjects with hepatitis B co-infection (see section 4.4).
Slovenian: Farmakokinetični podatki o osebah, sočasno okuženih s hepatitisom B, so omejeni (glejte poglavje 4.4).
English: This medicine does not require any special storage conditions.
Slovenian: Za shranjevanje tega zdravila niso potrebna posebna navodila.
English: Not all pack sizes may be available in your country.
Slovenian: Na trgu morda ni vseh navedenih pakiranj.
English: In HIV-1-infected adult subjects following dolutegravir 50 mg once daily, the steady-state pharmacokinetic parameters (geometric mean [%CV]) based on population pharmacokinetic analyses were AUC(0-24) = 53.6 (27) µg.h/mL, Cmax = 3.67 (20) µg/mL, and Cmin = 1.11 (46) µg/mL.
Slovenian: Pri odraslih osebah, okuženih z virusom HIV-1, so bili po dajanju 50 mg dolutegravirja enkrat dnevno farmakokinetični parametri v stanju dinamičnega ravnovesja (geometrijsko povprečje [% CV]) na osnovi populacijskih farmakokinetičnih analiz AUC(0-24) = 53,6 (27) g.h/ml, Cmax = 3,67 (20) g/ml in Cmin = 1,11 (46) g/ml.
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding (less than 36%).
Slovenian: V razponu terapevtskih odmerkov lamivudin kaže linearno farmakokinetiko in nizko vezavo na plazemske proteine (manj kot 36%).
English: The pharmacokinetics of dolutegravir following single dose oral administration to Japanese subjects appear similar to observed parameters in Western (US) subjects.
Slovenian: Farmakokinetika dolutegravirja po enkratnem peroralnem odmerku je bila pri japonskih preiskovancih podobna parametrom pri zahodnih (ZDA) preiskovancih.
English: Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs), and lamivudine belongs to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Slovenian: Dolutegravir spada v skupino protiretrovirusnih zdravil, ki se imenuje zaviralci integraze (INIs - integrase inhibitors), lamivudin pa sodi v skupino protiretrovirusnih zdravil, ki se imenuje zaviralci nukleozidne reverzne transkriptaze (ZNRT).
English: Dolutegravir and lamivudine are rapidly absorbed following oral administration.
Slovenian: Dolutegravir in lamivudin se po peroralnem dajanju hitro absorbirata.
English: • supplements or multivitamins containing calcium, iron or magnesium.
Slovenian: • dodatki ali multivitaminski pripravki, ki vsebujejo kalcij, železo ali magnezij.
English: Very common:
Slovenian: zelo pogosti:
English: The lamivudine AUC(0-∞) was not affected by a high fat meal.
Slovenian: Na AUC(0-) lamivudina zelo masten obrok ni imel vpliva.
English: In long-term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential.
Slovenian: V študijah karcinogenosti pri dolgoročni peroralni uporabi na podganah in miših lamivudin ni pokazal karcinogenega potenciala.
English: Dovato should be prescribed by physicians experienced in the management of HIV infection.
Slovenian: Zdravilo Dovato smejo predpisovati zdravniki, ki imajo izkušnje z zdravljenjem okužb z virusom HIV.
English: Polyvalent cationcontaining antacids are recommended to be taken 2 hours after or 6 hours before Dovato (see section 4.5).
Slovenian: Antacide, ki vsebujejo polivalentne katione, je priporočljivo vzeti 2 uri po ali 6 ur pred uporabo zdravila Dovato (glejte poglavje 4.5).
English: The IC50 for dolutegravir in various lab-strains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM.
Slovenian: Vrednost IC50 za dolutegravir pri različnih laboratorijskih sevih z uporabo PBMC je bila 0,5 nM, s celicami MT-4 pa so vrednosti segale od 0,7 do 2 nM.
English: Very common side effects These may affect more than 1 in 10 people:
Slovenian: Zelo pogosti neželeni učinki Ti se lahko pojavijo pri več kot 1 od 10 bolnikov:
English: The adverse reactions from clinical study and post-marketing experience are listed in Table 2 by body system, organ class and absolute frequency.
Slovenian: Neželeni učinki iz kliničnih preskušanj in na podlagi izkušenj v obdobju trženja so navedeni v Preglednici 2 glede na prizadeti organski sistem in pogostnost.
English: (organic cation transporter inhibition)
Slovenian: (zavrtje organskega kationskega prenašalca)
English: Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others.
Slovenian: Pri nekaterih ljudeh, ki jemljejo zdravilo Dovato ali druga kombinirana zdravila za zdravljenje okužbe z virusom HIV, obstaja večje tveganje za pojav resnih neželenih učinkov kot pri drugih.
English: • The active substances are dolutegravir and lamivudine.
Slovenian: • Učinkovini sta dolutegravir in lamivudin.
English: There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).
Slovenian: Opisani so primeri motenega delovanja mitohondrijev pri HIV-negativnih dojenčkih, ki so bili in utero in/ali postnatalno izpostavljeni nukleozidnim analogom (glejte poglavje 4.4).
English: Titanium dioxide (E171)
Slovenian: Obloga tablete hipromeloza (E464) makrogol titanov dioksid (E171)
English: Based on the lack of effect on the in vivo pharmacokinetics of the OAT substrate tenofovir, in vivo inhibition of OAT1 is unlikely.
Slovenian: Zaradi pomanjkanja učinka na farmakokinetiko OAT substrata tenofovirja in vivo, zaviranje OAT1 in vivo ni verjetno.
English: There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent.
Slovenian: Ni dokazov, da bi pogosti polimorfizmi encimov v presnovi zdravil klinično pomembno spremenili farmakokinetiko dolutegravirja.
English: It is unknown whether dolutegravir is excreted in human milk.
Slovenian: Ni znano, ali se dolutegravir pri človeku izloča v materino mleko.
English: A total of 1433 HIV-1 infected antiretroviral treatment-naïve adult subjects received treatment in the trials.
Slovenian: V preskušanjih je zdravilo prejemalo skupno 1433 odraslih preiskovancev, okuženih s HIV-1, ki predhodno še niso prejemali protiretrovirusnega zdravljenja.
English: Dovato is not recommended for use in patients with a creatinine clearance < 50 mL/min (see section 5.2).
Slovenian: Zdravila Dovato ni priporočljivo uporabljati pri bolnikih s kreatininskim očistkom < 50 ml/min (glejte poglavje 5.2).
English: - If Dovato is taken in a fasted state, such supplements should be taken a minimum 2 hours after or 6 hours before the intake of Dovato.
Slovenian: - Če se zdravilo Dovato jemlje na tešče, je potrebno te dodatke vzeti vsaj 2 uri po ali 6 pred uporabo zdravila Dovato
English: Lamivudine was not mutagenic in bacterial tests, but consistent with other nucleoside analogues, inhibits cellular DNA replication in in vitro mammalian tests such as the mouse lymphoma assay.
Slovenian: Lamivudin ni pokazal mutagenosti pri testih na bakterijah, vendar pa, skladno z drugimi nukleozidnimi analogi, inhibira replikacijo celične DNK v študijah in vitro na celicah sesalcev, npr. celicah mišjega limfoma.
English: GI intolerance in monkeys occurred at 30 times the human mg/kg equivalent dose (based on 50 kg human), and 11 times the human mg/m2 equivalent dose for a total daily clinical dose of 50 mg.
Slovenian: GI intoleranca se je pri opicah pojavila pri 30-kratniku ustreznega odmerka (v mg/kg) pri človeku (glede na človeka z maso 50 kg) ter pri 11-kratniku ustreznega odmerka (v mg/m 2) pri človeku za skupni dnevni klinični odmerek 50 mg.
English: No dose adjustment is necessary.
Slovenian: Prilagoditev odmerka ni potrebna.
English: For information around in vitro resistance, and cross resistance to other agents of the integrase- and NRTI class, please refer to the SmPCs of dolutegravir and lamivudine.
Slovenian: Za informacije o odpornosti in vitro in o navzkrižni odpornosti na druge učinkovine iz skupine zaviralcev integraze in NRTI glejte povzetek glavnih značilnosti zdravila za dolutegravir in lamivudin.
English: Limited data are available in adolescents receiving a daily dose of 300 mg of lamivudine.
Slovenian: Podatki o mladostnikih, ki so prejemali dnevni odmerek 300 mg lamivudina, so omejeni.
English: Effect of other medicinal products on the pharmacokinetics of dolutegravir and lamivudine
Slovenian: Učinki drugih zdravil na farmakokinetiko dolutegravirja in lamivudina
English: Following multipledose oral administration of lamivudine 300 mg once daily for seven days, the mean (CV) steady-state Cmax is 2.04 µg/mL (26%) and the mean (CV) AUC(0-24) is 8.87 µg.h/mL (21%).
Slovenian: Po peroralnem sedemdnevnem dajanju lamivudina v odmerku 300 mg enkrat dnevno znaša srednja (CV) v stanju dinamičnega ravnovesja Cmax 2,04 µg/ml (26 %) in srednja (CV) AUC(0-24) 8,87 µg.h/ml (21 %).
English: Psychiatric disorders: Common:
Slovenian: Psihiatrične motnje: pogosti:
English: Subjects were enrolled with a screening plasma HIV-1 RNA of 1000 c/mL to ≤500,000 c/mL.
Slovenian: V raziskavo so bili vključeni preiskovanci s HIV-1 RNK v plazmi od 1000 kopij/ml do ≤ 500.000 kopij/ml.
English: • medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
Slovenian: • redna uporaba zdravil (večinoma raztopine), ki vsebujejo sorbitol ali druge sladkorne alkohole (npr. ksilitol, manitol, laktitol ali maltitol)
English: Dose reduction is required for patients with creatinine clearance < 50 mL/min (see section 4.2).
Slovenian: Pri bolnikih s kreatininskim očistkom < 50 ml/min je potrebno odmerek zmanjšati (glejte poglavje 4.2).
English: The median or mean IC50 values for lamivudine against lab-strains of HIV-1 ranged from 0.007 to 2.3 µM.
Slovenian: Mediane ali povprečne vrednosti IC50 za lamivudin proti laboratorijskim sevom HIV-1 so segale od 0,007 do 2,3 M.
English: The results from two in vivo rat micronucleus tests with lamivudine were negative.
Slovenian: Rezultati mikronukleus testa, izvedenega in vivo na podganah z lamivudinom, so bili negativni.
English: Baseline Plasma Viral Load (copies/mL)
Slovenian: Izhodiščno virusno breme v plazmi (kopij/ml)
English: * The results of the pooled analysis are in line with those of the individual studies, for which the primary endpoint (difference in proportion <50 copies/mL plasma HIV-1 RNA at Week 48 based on the Snapshot algorithm for dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil /emtricitabine FDC) was met.
Slovenian: * Rezultati združene analize se ujemajo z rezultati vsake posamezne od obeh študij, v katerih je bil dosežen primarni opazovani dogodek (razlika v deležih < 50 kopij/ml HIV-1 RNK v plazmi po 48 tednih (na podlagi algoritma Snapshot) za kombinacijo dolutegravirja in lamivudina v primerjavi s kombinacijo dolutegravirja in dizoproksiltenofovirata/emtricitabina FDC).
English: Metformin is eliminated renally and, therefore, it is of importance to monitor renal function when co-treated with Dovato.
Slovenian: Metformin se izloča skozi ledvice, zato je med sočasnim zdravljenjem z zdravilom Dovato pomembno kontrolirati delovanje ledvic.
English: The effect of severe hepatic impairment on the pharmacokinetics of dolutegravir has not been studied.
Slovenian: Vpliva hude okvare jeter na farmakokinetiko dolutegravirja niso raziskali.
English: Lamivudine is predominately cleared by renal excretion of unchanged lamivudine.
Slovenian: Lamivudin se v glavnem izloča skozi ledvice v nespremenjeni obliki.
English: • stomach (abdominal) pain or discomfort
Slovenian: • bolečine v trebuhu (abdominalne bolečine) ali nelagodje v želodcu
English: Polymorphisms in drug metabolising enzymes
Slovenian: Polimorfizmi encimov v presnovi zdravil
English: In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).
Slovenian: V metaanalizi farmakogenomskih vzorcev iz kliničnih študij zdravih preiskovancev so imele osebe z genotipi UGT1A1 (n = 7), ki povzročajo počasno presnovo dolutegravirja, 32 % manjši očistek dolutegravirja in 46 % večjo AUC kot preiskovanci z genotipi, ki so povezani z normalno presnovo z UGT1A1 (n = 41).
English: Dovato should not be taken with any other medicinal product containing dolutegravir or lamivudine, except where a dose adjustment of dolutegravir is indicated due to drug-drug interactions (see section 4.5).
Slovenian: Zdravila Dovato se ne sme uporabljati z nobenim drugim zdravilom, ki vsebuje dolutegravir ali lamivudin, razen v primeru prilagoditve odmerka dolutegravirja zaradi interakcij z drugimi zdravili (glejte poglavje 4.5).
English: In vivo, dolutegravir did not have an effect on midazolam, a CYP3A4 probe.
Slovenian: Dolutegravir in vivo ni vplival na midazolam, testni substrat za CYP3A4.
English: Administration of a single Dovato tablet with a high fat meal increased dolutegravir AUC(0-∞) and Cmax by 33% and 21%, respectively, and decreased the lamivudine Cmax by 30% compared to fasted conditions.
Slovenian: Uporaba ene tablete zdravila Dovato skupaj z zelo mastnim obrokom je povečala AUC(0-) dolutegravirja za 33% in koncentracijo dolutegravirja Cmax za 21 % ter zmanjšala koncentracijo lamivudina Cmax za 30 % v primerjavi s pogoji na tešče.
English: Multivitamins (containing calcium, iron and magnesium) /Dolutegravir (fasted intake)
Slovenian: multivitaminski pripravki (ki vsebujejo kalcij, železo in magnezij)/dolutegravir (jemanje na tešče)
English: Dolutegravir is primarily metabolized and eliminated by the liver.
Slovenian: Dolutegravir se presnavlja in izloča predvsem z jetri.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Slovenian: V okviru imunske reaktivacije je bil opisan tudi pojav avtoimunskih bolezni (npr. pojav Gravesove bolezni in avtoimunskega hepatitisa), toda opisani čas do začetka je bolj spremenljiv in ti učinki se lahko pojavijo veliko mesecev po uvedbi zdravljenja.
English: There are no data on the effects of dolutegravir or lamivudine on human male or female fertility.
Slovenian: Ni podatkov o vplivu dolutegravirja ali lamivudina na moško ali žensko plodnost pri ljudeh.
English: While the total dolutegravir concentration in plasma was similar, a 1.5 to 2 fold increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment compared to healthy controls.
Slovenian: Medtem ko je bila skupna koncentracija dolutegravirja v plazmi podobna, so v primerjavi z zdravimi kontrolnimi osebami pri preiskovancih z zmerno okvaro jeter opazili 1,5 - 2-kratno povečanje izpostavljenosti nevezanemu dolutegravirju.
English: In patients with moderate renal impairment a dose adjustment of metformin should be considered when coadministered with Dovato, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration (section 4.4).
Slovenian: Pri bolnikih z zmerno okvaro ledvic je treba v primeru sočasne uporabe z zdravilom Dovato razmisliti o prilagoditvi odmerka metformina, ker imajo bolniki z zmerno okvaro ledvic zaradi večje koncentracije metformina večje tveganje za laktacidozo (glejte poglavje 4.4).
English: In the pooled GEMINI studies a mean change from baseline of 10.3 µmol/L (range: -36.3 µmol/L to 55.7 µmol/L) was observed after 48 weeks of treatment.
Slovenian: V združenih študijah GEMINI so po 48 tednih zdravljenja opazili povprečno spremembo 10,3 µmol/l (razpon: od -36,3 µmol/l do 55,7 µmol/l) v primerjavi z izhodiščem.
English: The combination of Dovato with cladribine is not recommended (see section 4.5).
Slovenian: Kombinacija zdravila Dovato s kladribinom ni priporočljiva (glejte poglavje 4.5).
English: Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant effect on the exposure to dolutegravir.
Slovenian: Populacijska farmakokinetična analiza je pokazala, da sočasna okužba z virusom hepatitisa C nima klinično pomembnega vpliva na izpostavljenost dolutegravirju.
English: Lamivudine has not shown any genotoxic activity in the in vivo studies.
Slovenian: V študijah in vivo lamivudin ni pokazal nobenega genotoksičnega delovanja.
English: Dolutegravir has a terminal half-life of ~14 hours.
Slovenian: Končni razpolovni čas dolutegravirja je ~14 ur.
English: Fertility studies in rats have shown that dolutegravir or lamivudine have no effect on male or female fertility.
Slovenian: Študija plodnosti pri podganah je pokazala, da dolutegravir in lamivudin ne vplivata na plodnost samcev ali samic.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Slovenian: Poročali so tudi o pojavu avtoimunih bolezni, kot sta Gravesova bolezen in avtoimunski hepatitis, vendar pa je čas do pojava teh dogodkov, ki ga navajajo v poročilih, precej različen, saj lahko pride do njih tudi več mesecev po začetku zdravljenja (glejte poglavje 4.4).
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Slovenian: Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - “combination antiretroviral therapy”) nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
English: In a randomized, dose-ranging trial, HIV-1-infected subjects treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity, with mean decline in HIV-1 RNA of 2.5 log10 at day 11 for 50 mg dose.
Slovenian: V randomiziranem preskušanju razpona odmerkov je bilo pri preiskovancih, okuženih z virusom HIV-1, ki so prejemali monoterapijo z dolutegravirjem (ING111521), dokazano hitro in od odmerka odvisno protivirusno delovanje; povprečno zmanjšanje HIV-1 RNK je bilo pri odmerku 50 mg 11. dan 2,5 log10.
English: In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).
Slovenian: V študijah vpliva na razmnoževanje pri živalih za dolutegravir niso bili ugotovljeni negativni učinki na razvoj, vključno z okvarami nevralne cevi (glejte poglavje 5.3).
English: Dolutegravir has been associated with an increase in serum creatinine occuring in the first week of treatment when administered with other antiretroviral medicinal products.
Slovenian: Spremembe v izvidih laboratorijskih biokemijskih preiskav Dolutegravir je bil povezan z zvišanjem serumskega kreatinina, ki se je pojavilo v prvem tednu zdravljenja med uporabo z drugimi protiretrovirusnimi zdravili.
English: Dovato may be administered with or without food.
Slovenian: Zdravilo Dovato se lahko jemlje s hrano ali brez nje.
English: No specific symptoms or signs have been identified following acute overdose with dolutegravir or lamivudine, apart from those listed as adverse reactions.
Slovenian: Po akutnem zaužitju prevelikega odmerka dolutegravirja ali lamivudina niso poročali o posebnih simptomih ali znakih, razen tistih, ki so navedeni kot neželeni učinki.
English: Lamivudine ↔ Ledipasvir ↔ Sofosbuvir ↔
Slovenian: lamivudin  ledipasvir  sofosbuvir 
English: In 13 treatment-naïve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18 ng/mL (comparable to unbound plasma concentration, and above the IC50).
Slovenian: Pri 13 predhodno še nezdravljenih osebah je bila pri stabilnem režimu zdravljenja s kombinacijo dolutegravirja in abakavirja/lamivudina povprečna koncentracija dolutegravirja v cerebrospinalni tekočini 18 ng/ml (to je primerljivo z nevezano koncentracijo v plazmi ter presega IC50).